Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.

This publication has 49 references indexed in Scilit:

• Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer
  Cancer, 2008
• Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study
  Journal of Clinical Oncology, 2008
• Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer
  Urology, 2008
• The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort study
  BJU International, 2006
• Association of Adiponectin with Coronary Heart Disease and Mortality: The Rancho Bernardo Study
  American Journal of Epidemiology, 2006
• Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
  Journal of Clinical Oncology, 2006
• Bone Mineral Density and Lipid Changes During 5 Years of Follow-up in a Study of Prevention of Breast Cancer with Toremifene in Healthy, High-risk Pre- and Post-menopausal Women
  Breast Cancer Research and Treatment, 2005
• Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids
  Breast Cancer Research and Treatment, 2004
• Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic Hyperplasia
  Journal of Urology, 1995
• Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
  New England Journal of Medicine, 1984